Anti-PD-1: When to Stop Treatment.

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Metastatic melanoma treatment often involves immune checkpoint blockade (ICB).
• Determining the optimal duration of ICB therapy is an ongoing clinical challenge.
• Current data suggest ICB can be stopped electively or due to toxicity with manageable progression risk.

Purpose of the Study:

• To review published data on ICB treatment duration in metastatic melanoma.
• To analyze outcomes following ICB discontinuation.
• To evaluate the efficacy of ICB re-introduction in this patient population.

Main Methods:

• Systematic review of published studies on ICB treatment duration.
• Analysis of patient outcomes after elective or toxicity-driven ICB cessation.
• Review of data on treatment re-initiation following discontinuation.

Main Results:

• Disease control is often maintained after ICB discontinuation.
• Stopping ICB reduces adverse events and healthcare costs for responders.
• Elective discontinuation after one year appears safe, with acceptable progression risk.
• Response depth is a key predictor of sustained response; metabolic response may gain importance.

Conclusions:

• Immune checkpoint blockade in metastatic melanoma can be discontinued electively or due to toxicity.
• One year of ICB therapy may be a safe duration for elective discontinuation.
• Response depth and metabolic response are crucial for predicting outcomes after treatment cessation.